pomalidomide-c4-oh

Pomalidomide-C4-OH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-4-OH (E3 ligase Ligand 2) (Cereblon ligand 2) is the Thalidomide-based Cereblon ligand used to recruit of CRBN protein. Thalidomide-4-OH (Cereblon ligand 2) is a linker to form PROTACs

Pomalidomide-PEG3-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

Pomalidomide-PEG2-OH enables the synthesis of molecules for targeted protein degradation and PROTAC (proteolysis-targeting chimeras) technology.

Butanoic acid, 4-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]- (4-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]butanoic acid) is a Cereblon ligand with alkyl linker and terminal acid for onward chemistry.

Pomalidomide 4'-PEG2-azide is a synthetic E3 ligase ligand-linker conjugate, comprising a Pomalidomide-based cereblon ligand and a linker.

Pomalidomide-PEG4-C-COOH (E3 Ligase Ligand-Linker Conjugates 1) is a synthesized E3 ligase ligand-linker conjugate that combines the Pomalidomide-based cereblon ligand and 4-unit PEG linker used in PROTAC technology.

Pomalidomide 4'-alkylC6-azide, a Pomalidomide-based cereblon (CRBN) ligand, facilitates the recruitment of CRBN protein. It is designed to attach to a protein through a linker, enabling the formation of PROTAC [1].

Pomalidomide 4'-PEG3-azide is a chemically synthesized E3 ligase ligand-linker conjugate that incorporates the cereblon ligand derived from Pomalidomide, along with a linker. This compound is utilized in the synthesis of iRucaparib-TP3 (Compound 3), an effective PARP1 degrader developed through the PROTAC strategy and derived from Rucaparib.

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC8 linker with terminal acid ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

CC-17368 is a bio-active chemical.

Lenalidomide-4-OH is a cereblon (CRBN) ligand derived from Lenalidomide, utilized in the recruitment of the CRBN protein. It can be conjugated to the protein ligand via a linker, facilitating the formation of PROTAC.

Pomalidomide 4'-PEG5-amine, a cereblon ligand designed for PROTAC research and development, features an integrated E3 ligase ligand and a PEG5 linker ending in an amine for easy conjugation to target protein ligands. It is among a series of functionalized tool molecules specifically crafted for PROTAC R&D.

DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1]. DP-C-4 (1-50 μM; 24 hours) has degradation effects on EGFR and PARP simultaneously in a dose-dependent manner in SW1990 cells[1]. [1]. Mengzhu Zheng, et al. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP. J Med Chem. 2021 May 26.

Pomalidomide 4'-PEG5-azide, a cereblon (CRBN) ligand based on Pomalidomide, facilitates the recruitment of CRBN protein. It can be conjugated through a linker to another ligand, forming a proteolysis-targeting chimera (PROTAC) [1].

Pomalidomide-6-OH, a Pomalidomide-derived cereblon (CRBN) ligand, facilitates the recruitment of CRBN protein. This compound can be tethered to a protein ligand through a linker to create a proteolysis-targeting chimeric molecule (PROTAC [1]).